SenesTech, Inc. Stock: price and directors' dealings · United States · SEC (Form 4)

About SenesTech, Inc.

SenesTech, Inc. (ticker: SNES) is a U.S.-listed company trading on the Nasdaq Stock Market in the United States. It is a small-cap, niche environmental and specialty pest-management business rather than a broad-based industrial supplier. The company was incorporated in the State of Nevada in July 2004 and is headquartered in Phoenix, Arizona, where it also operates its manufacturing site. For French, Belgian, and Swiss investors, SenesTech is best understood as a differentiated commercial-stage company focused on a specific and relatively underserved segment: fertility control for rat populations. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1680378/000162828025012408/snes-20241231.htm?utm_source=openai)) SenesTech’s core business is built around proprietary solutions designed to manage animal pest populations through fertility control instead of traditional lethal control. Its flagship product is ContraPest, which the company describes as the only EPA-registered birth control product for both male and female rats. The portfolio also includes Evolve and the Elevate Bait System, which extends the company’s reach into additional use cases, including agricultural settings. This gives SenesTech a clear product identity: it is not a general pest-control company, but a specialist in humane rodent population management with a sustainability-oriented value proposition. ([senestech.com](https://senestech.com/pages/about?utm_source=openai)) From a competitive standpoint, the company’s appeal lies in its differentiation. Traditional rodent control relies heavily on poisons and traps, whereas SenesTech positions its technology as a longer-term population-reduction tool that can be used by pest management professionals, zoos, sanctuaries, and agricultural customers. That specialization may create strategic advantages in accounts where public perception, safety, or sustainability matter, but it also means the company depends on customer education, regulatory approvals, and professional adoption to scale. In other words, SenesTech competes more on product uniqueness than on price or distribution breadth. ([senestech.com](https://senestech.com/pages/humane-rat-control?utm_source=openai)) Geographically, SenesTech’s operations are centered in the United States. The company has also emphasized national availability for some products, including the Elevate Bait System, after California regulatory approval expanded its market reach. That suggests a U.S.-centric commercialization model with potential for broader penetration across fifty states, though the business remains early in its scaling phase. ([senestech.com](https://senestech.com/blogs/news/elevate-bait-system%E2%84%A2-with-contrapest%C2%AE-is-now-available-in-california?utm_source=openai)) Recent corporate developments highlight a transitional period in leadership. In January 2026, CEO Joel L. Fruendt announced his retirement, with his departure tied to the earlier of June 30, 2026 or the appointment of a successor. On May 6, 2026, the company appointed Michael Edell as President and Chief Executive Officer. The company also continued to file SEC reports around year-end 2025 and the first quarter of 2026, underscoring ongoing public-market disclosure as it executes through this leadership change. Overall, SenesTech is a Nasdaq-listed U.S. micro-cap with an innovation-led thesis centered on humane rodent fertility control, regulatory expansion, and commercial adoption. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1680378/000162828026003905/snes-20260128.htm?utm_source=openai))